<DOC>
	<DOCNO>NCT02210806</DOCNO>
	<brief_summary>This study evaluate efficacy , dose-ranging safety profile A006 , Albuterol dry powder inhaler ( DPI ) , dose range 110 220 mcg per dose comparison DPI Placebo Control Albuterol meter dose inhaler ( MDI ) Active Control .</brief_summary>
	<brief_title>Albuterol DPI ( A006 ) Clinical Study-B3 : Efficacy , Dose-ranging Safety Evaluation</brief_title>
	<detailed_description>This study design evaluate efficacy safety profile A006 assist identify optimum dose A006 future clinical study . Proventil® HFA MDI , currently market Albuterol MDI product , use Active Control . The study also employ Placebo Control DPI , configuration A006 DPI except contains active ingredient .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Generally healthy , male female adult , 1855 year age Screening With mildtomoderate persistent asthma least 6 month prior Screening , use inhaled βagonist ( ) asthma control Demonstrating Screening Baseline FEV1 50.0 85.0 % predict normal Demonstrating ≥ 15.0 % Airway Reversibility FEV1 within 30 min inhale 2 actuation Proventil® MDI ( 180 mcg ) Screening Demonstrating Peak Inspiratory Flow Rate ( PIF ) within 80150 L/min ( train ) , least 2 time consecutively maximum 5 attempt Demonstrating proficiency use DPI MDI training Females childbearing potential must nonpregnant , nonlactating ; male female enrol study must agree practice clinically acceptable form birth control ( include limit , abstinence , double barrier , etc ) Having properly consent participate trial A smoking history ≥ 5 packyears , smoke within 6 month prior Screening Upper respiratory tract infection low respiratory tract infection within 6 week , prior Screening Asthma exacerbation require emergency care hospitalize treatment , within 4 week prior Screening Any current recent respiratory condition , per investigator discretion , might significantly affect pharmacodynamic response study drug , include cystic fibrosis , bronchiectasis , tuberculosis , emphysema , significant respiratory disease besides asthma Concurrent clinically significant cardiovascular ( e.g . hypertension tachyarrhythmia bradyarrhythmia ) , hematological , renal , neurologic , hepatic , endocrine , psychiatric , malignant , illnesses opinion investigator could impact conduct , safety evaluation study Known intolerance hypersensitivity ingredient study drug DPI Proventil® HFA MDI ( i.e. , Albuterol , sulfate , lactose , milk protein , HFA134a , oleic acid , ethanol ) Baseline ECG Screening Visit 1 show single multiple premature ventricular contraction ( PVC ) Baseline ECG Screening Visit 1 confirm ( perform second ECG ) QTc read great 450ms Use prohibit drug failure observe drug washout restriction Having clinical drug/device study last 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Mild-to-moderate persistent asthma</keyword>
	<keyword>Mild asthma</keyword>
	<keyword>Moderate asthma</keyword>
	<keyword>Persistent asthma</keyword>
</DOC>